Hu Li
Research Subjects
Hu Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Hongfeng Li
Shanghai Miracogen, Shanghai, Peoples R China
2 shared publicationsChaohong Hu
Research and Development, Shanghai Miracogen , Suite 4E, Bldg. 3, No. 1238 Zhangjiang Road, Pudong District, Shanghai 201203, China
1 shared publicationLili Xiao
Research and Development, Shanghai Miracogen , Suite 4E, Bldg. 3, No. 1238 Zhangjiang Road, Pudong District, Shanghai 201203, China
1 shared publicationLingrui Li
Research and Development, Shanghai Miracogen , Suite 4E, Bldg. 3, No. 1238 Zhangjiang Road, Pudong District, Shanghai 201203, China
1 shared publicationWenchao Liu
Research and Development, Shanghai Miracogen , Suite 4E, Bldg. 3, No. 1238 Zhangjiang Road, Pudong District, Shanghai 201203, China
1 shared publicationXiao Zhang
Research and Development, Shanghai Miracogen , Suite 4E, Bldg. 3, No. 1238 Zhangjiang Road, Pudong District, Shanghai 201203, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2021
- Published by AME Publishing Company in Translational Breast Cancer Research
- Vol. 2, 29
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer Hu Li, Hongfeng Li
- 1 October 2021
- Published by AME Publishing Company in Translational Breast Cancer Research
- Vol. 2, 29
Open AccessA narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer Hu Li, Hongfeng Li
- Open Access
- 19 July 2021
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 4 (3) , 175-184
Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors
Background: ERBB2 is a proto-oncogene of multiple cancers including breast and gastric cancers with HER2 protein overexpression or gene amplification and has been proven clinically as a valid target for these cancers. HER2-targeting agents such as Herceptin®, Kadcyla® and ENHERTU® have been approved by the FDA for the treatment of breast cancer, but these drugs still face the challenge of acquired resistance and/or severe adverse reactions in clinical use. Therefore, there is significant unmet medical need for developing new agents that are more effective and safer for patients with advanced HER2-positive solid tumors including breast and gastric cancers. Methods: We report here the making of MRG002, a novel HER2-targeted ADC, and preclinical characterization including pharmacology, pharmacodynamics and toxicology and discuss its potential as a novel agent for treating patients with HER2-positive solid tumors. Results: MRG002 exhibited similar antigen binding affinity but much reduced ADCC activity compared to trastuzumab. In addition to potent in vitro cytotoxicity, MRG002 showed tumor regression in both high- and medium-to-low HER2 expressing in vivo xenograft models. Furthermore, MRG002 showed enhanced antitumor activity when used in combination with an anti-PD-1 antibody. Main findings from GLP-compliant toxicity studies are related to the payload and are consistent with literature report of other ADCs with MMAE. Conclusion: MRG002 has demonstrated a favorable toxicity profile and potent antitumor activities in the breast and gastric PDX models with varying levels of HER2 expression, and/or resistance to trastuzumab or T-DM1. A phase I clinical study of MRG002 in patients with HER2-positive solid tumors is ongoing (CTR20181778).
- 19 July 2021
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 4 (3) , 175-184
Open AccessPreclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors
Background: ERBB2 is a proto-oncogene of multiple cancers including breast and gastric cancers with HER2 protein overexpression or gene amplification and has been proven clinically as a valid target for these cancers. HER2-targeting agents such as Herceptin®, Kadcyla® and ENHERTU® have been approved by the FDA for the treatment of breast cancer, but these drugs still face the challenge of acquired resistance and/or severe adverse reactions in clinical use. Therefore, there is significant unmet medical need for developing new agents that are more effective and safer for patients with advanced HER2-positive solid tumors including breast and gastric cancers. Methods: We report here the making of MRG002, a novel HER2-targeted ADC, and preclinical characterization including pharmacology, pharmacodynamics and toxicology and discuss its potential as a novel agent for treating patients with HER2-positive solid tumors. Results: MRG002 exhibited similar antigen binding affinity but much reduced ADCC activity compared to trastuzumab. In addition to potent in vitro cytotoxicity, MRG002 showed tumor regression in both high- and medium-to-low HER2 expressing in vivo xenograft models. Furthermore, MRG002 showed enhanced antitumor activity when used in combination with an anti-PD-1 antibody. Main findings from GLP-compliant toxicity studies are related to the payload and are consistent with literature report of other ADCs with MMAE. Conclusion: MRG002 has demonstrated a favorable toxicity profile and potent antitumor activities in the breast and gastric PDX models with varying levels of HER2 expression, and/or resistance to trastuzumab or T-DM1. A phase I clinical study of MRG002 in patients with HER2-positive solid tumors is ongoing (CTR20181778).